Indivior Share Discussion Threads

[youngers] 28/4/2022 08:36

Another strong quarter with growth momentum holding or even increasing in the all important sublocade.

My only criticism is they again released at wrong time. They said midday.

Slough, UK, and Richmond, VA, April 7, 2022 - Indivior PLC (LON: INDV) today announced that it will release its Q1 2022 results on April 28(th) at 12:00 GMT (7:00 a.m. U.S. Eastern).

[gregmorg] 28/4/2022 08:23

Yes, Steeplejack, a pretty good read as far as I am concerned. The further share buy back is a nice touch which certainly won't do any harm! Will wait to see how the briefing goes later.

[steeplejack] 28/4/2022 07:57

Solid trading progress all round.Share buy back programme plus planned US listing in Sept.How the shares trade today is anyones bet of course.

[misca2] 27/4/2022 21:32

The 2022 AGM will be held on Thursday May 5, 2022, at 11.00am at the offices of Freshfields Bruckhaus Deringer LLP, 100 Bishopsgate, London EC2P 2SR.

[disc0dave45] 09/4/2022 19:30

From a technical perspective it is currently overbought so personally wouldnt be surprised to see it pullback on results, the caveat being conformation of US listing.It is 10% below consensus share price forecasts but assume that's for this FY end.Looking at FY23 it's still good value IMO (forward PE only 16.5x) and I expect them to beat forecasts, and if they get the listing that will generate significant value, or someone will see the value and make a play for it.

[grupo guitarlumber] 09/4/2022 12:19

Resistence at 333.50p with Support at 286.60p

quite a spread

seems to be very toppy and more than fairly valued

The coming weeks and month should clarify all

[disc0dave45] 08/4/2022 17:37

There was a gap on 1st April at around 288 which may need filling so will be interesting to see if it does pull back on results.

[waldron] 08/4/2022 17:04

[United Kingdom] INDIVIOR PLC (INDV)


Delayed London Stock Exchange - 04/08 04:35:18 pm BST

328.00 GBX +3.08%


BREAK AND GAP UP TO BE HOPEFULLY COMFIRMED EARLY PART OF NEXT WEEK

[disc0dave45] 08/4/2022 15:37

Strong momentum here IMO up to results :)

[the grumpy old men] 08/4/2022 12:30

Seems resistence pencilled in at 325.30p

[the grumpy old men] 08/4/2022 12:29

319.90 GBX +0.53%

[the grumpy old men] 08/4/2022 12:27

Indivior to Announce Q1 2022 Results and Host Webcast on April 28(th)

Slough, UK, and Richmond, VA, April 7, 2022 - Indivior PLC (LON: INDV) today announced that it will release its Q1 2022 results on April 28(th) at 12:00 GMT (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com .

Mark Crossley, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 13:00 GMT (8:00 a.m. U.S. Eastern) on April 28(th) .

Access to the Live Webcast Presentation

The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins.

The webcast link is hxxps://edge.media-server.com/mmc/p/ogy6nn93 .

Participants may access the presentation telephonically :

-- US participants 1-646-741-3167
-- International participants [phone]

Please reference confirmation ID 6687840. A replay of the presentation will be available at www.indivior.com .

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .

[disc0dave45] 06/4/2022 18:29

As Q1 is about 3 weeks away I'd guess there could be some positive news on the listing.

[waldron] 04/4/2022 09:37

296.8 GBX +4.14%

[florenceorbis] 04/4/2022 09:25

M arch 30, 2022

Indivior PLC (the 'Company')

Annual Report and Accounts and Notice of Annual General Meeting

The Company has today posted or made available to shareholders the following documents:

- Annual Report and Accounts for the year ended December 31, 2021 (the '2021 Annual Report and Accounts');

- Notice of 2022 Annual General Meeting ('AGM'); and
- Form of Proxy for the AGM.

In accordance with LR 9.6.1 and DTR 6.3.5, a copy of each of these documents has been submitted to the FCA and will shortly be available for inspection in unedited full text at .

The 2021 Annual Report and Accounts and Notice of AGM can also be viewed on the Company's website at:

- ; and
-

AGM meeting arrangements

The 2022 AGM will be held on Thursday May 5, 2022, at 11.00am at the offices of Freshfields Bruckhaus Deringer LLP, 100 Bishopsgate, London EC2P 2SR.

[florenceorbis] 04/4/2022 09:23

31 March 2022

Indivior to Commence Formal Shareholder Consultations on Additional US Listing

Richmond, VA, March 31, 2022 - Indivior PLC, (LON: INDV) today announced that further to its announcement on February 16, 2022, it is commencing formal consultations with shareholders on the potential for an additional listing of Indivior shares in the US on a major stock exchange.

The Board believes that an additional US listing is likely to be beneficial to elevating the Group's profile in its largest market. In coming to its view, the Board considered the following key elements of the Group's strategy, structure and opportunity:

-- Approximately 80% of Group's net revenue is generated in the US;

-- The US currently is, and is expected to remain, the Group's largest and highest value market for its key treatments (SUBLOCADE (R) and PERSERIS (R) );

-- Healthcare comprises approximately 20% of US gross domestic product (GDP) and, as such, the US contains the largest pool of biopharma-focused investors and research analyst coverage;

-- The CEO and a majority of the Group's leadership team are based in the US;
-- 40%-plus of shareholders are based in North America; and
-- Provides a US stock currency for potential business development.

The Board looks forward to receiving investor feedback during the consultations and, if supportive, the Board intends to put forward a formal shareholder resolution in September of this year that would facilitate an additional listing in the US.

Comment by Graham Hetherington, Chair of the Board

In assessing Indivior's optimal listing structure, the Board's approach is always to consider what is in the best interests of the Group and all of its stakeholders over the long-term. The Board believes that an additional US listing in the near-term would be beneficial because we believe it will raise the Group's profile in its highest value market and potentially attract a broader group of biopharma shareholders. Longer-term, it also provides the Group with the optionality to pursue a primary or sole US listing, if appropriate.

We have received initial positive feedback from a broad range of shareholders on the potential of an additional US listing. We are, however, mindful that this is a complex issue for shareholders, and we look forward to commencing a period of formal consultations with our shareholders. We will listen carefully to all shareholder feedback and expect to make a further announcement following the conclusion of shareholder consultations, which is likely to be in July of this year in conjunction with the Group's H1 2022 results.

Background

In conjunction with its FY 2021 results release on February 16, 2022, the Group's Board indicated that it had been assessing the optimal listing structure for Indivior shares and that its preliminary view was that an additional listing of Indivior shares on a major US stock exchange is likely to be beneficial to the Group's profile and ability to attract a broader group of biopharma-focused investors and research analysts. The Board is now formally commencing further consultations with institutional shareholders on the potential of such an additional US listing.

More detail on the US additional listing considerations can be found in the Consultation presentation on the Group's website. If supported by shareholders, the key considerations and anticipated timings for an additional US listing are as follows:

-- Additional listing of Indivior shares on a major US stock exchange (i.e., NASDAQ, NYSE);
-- Full premium London Stock Exchange listing maintained;
-- FTSE indexation maintained;

-- Requires shareholder approval by a majority of 75% (of votes cast) of a resolution to amend Indivior's articles of association to facilitate settlement of its shares in the UK and US;

-- Extraordinary General Meeting of shareholders to obtain such approval in September 2022; and
-- Earliest implementation of additional US listing in Spring 2023.

[florenceorbis] 04/4/2022 09:21

And despite this news


Indivior PLC Auditor Raises 'Going Concern' Doubt
03/30/2022 BST


Indivior PLC filed its Annual on Mar 30, 2022 for the period ending Dec 31, 2021. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

[youngers] 04/4/2022 09:17

Always nice to see this sort of move on no news flow.

[la forge] 31/3/2022 19:45

Price (GBX)
280.20 -0.14% (-0.40)

[gregmorg] 31/3/2022 14:15

Nice to see the planned dual listing plans/consultations are moving along. September being the next focal point.

I confess I am less keen on the long term suggestion/possibility of a single US market listing as I happen to like the UK visibility. Yet I fully accept that there are other considerations ! !

[waldron] 25/3/2022 10:26

Indivior: Morgan Stanley starts online weighted tracking by targeting 330 GBp.

[florenceorbis] 13/3/2022 11:30

As yet no go, any idea as to time line if it does get US Listing

"Finally, together with the Board we have been assessing the optimal listing structure for Indivior's shares. Our preliminary view is that an additional US listing is likely to be beneficial to the Group's profile and visibility, as approximately 80% of the Group's net revenue is generated in the US. We are aware that this is an important topic, and the Board and management intend to consult extensively with shareholders before concluding on any future path."



Youngers
13 Mar '22 - 10:23 - 3428 of 3428
0 0 0
I wonder whether they’d use the US listed company to undertake a reverse takeover so the listing is switched from U.K. to US.

[youngers] 13/3/2022 10:23

I wonder whether they’d use the US listed company to undertake a reverse takeover so the listing is switched from U.K. to US.